On March 4, Amy Vaccine announced on the Hong Kong Stock Exchange that the company's R&D of the 13-valent pneumococcal conjugate vaccine, serum-free iterative rabies vaccine, and 23-valent pneumococcal polysaccharide vaccine have all completed the on-site work of Phase III clinical trials and are carrying out various preparations before the new drug application for market launch, planning to complete the application and launch in 2024. In addition, the company has completed the construction of production workshops for the above three vaccines and has completed the production of Phase III clinical trial samples in the completed workshops.

Vaccine industry leader Amy Vaccine (06660.HK) has recently released several R&D progress announcements. Not only has the 13-valent pneumococcal conjugate vaccine submitted a pre-application for market registration, but also blockbuster products such as the 13-valent pneumococcal conjugate vaccine, serum-free iterative rabies vaccine, and 23-valent pneumococcal polysaccharide vaccine are planned to be completed and filed for market launch within the year. Additionally, there are blockbuster new products like the quadrivalent meningococcal conjugate vaccine and adsorbed acellular pertussis-diphtheria-tetanus-Haemophilus influenzae type b (HIB) combination vaccine that are rapidly advancing in research and development. Entering 2024, Amy Vaccine's blockbuster innovative iterative products have entered an intensive filing period, and the company is accelerating the formation of new quality production forces.

Recently, the phase summary meeting of the Guangdong Shunde District Jun'an Town Spark Project for eliminating the hazards of viral hepatitis was held. The meeting brought together representatives from the China Hepatitis Foundation, the Chinese Preventive Medicine Association, Guangdong provincial and municipal disease prevention and control centers, health departments, and relevant medical institutions to summarize the experience of eliminating the hazards of hepatitis under the Spark Project and explore how to replicate and promote it nationwide.

On December 27th, Aimei vaccines announced that the company held an investor open day event on December 22nd. Nearly 40 investment institutions, including CITIC Securities, CITIC Construction Investment Securities, Guotai Junan Securities, and CMB International Securities, visited Aimei vaccines' bacterial vaccine industrialization base and mRNA and viral vaccine industrialization production bases in Ningbo. They conducted on-site visits, discussions, and exchanges to gain a detailed understanding of the company's upcoming innovative vaccine products set to go public and the status of their production workshops, as well as the company's product pipeline layout and development plans.

According to the quarterly index review results announced by MSCI earlier in November, Aimei vaccines (06660) was selected as a component of the MSCI Global Small Cap Index. This adjustment took effect after the market closed yesterday (November 30th).

On October 17th, Aimei vaccines announced that the Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (referred to as the 13-valent pneumococcal vaccine) is about to enter the stage of statistical unblinding. As of now, the trial results obtained indicate that the vaccine has good safety and immunogenicity.